GentiBio
Jennifer Hu is the Associate Director of Vector Analytics. Jennifer is an analytical biochemist by training and received her B.S. in Chemical Biology from UC Berkeley and her Ph.D. in Chemistry from MIT. Prior to joining Gentibio, Jennifer held technical, strategy, and team leadership roles in Cell Therapy Development at Juno/Celgene/Bristol Myers Squibb. There, her work focused on advancing product and platform understanding by driving and implementing analytical and impurity strategies for drug products, vector, and gene editing reagents. Prior to her experience in cell therapy, Jennifer worked in the Process Technical Development organization at Genentech on chromatographic, mass spectrometry, and electrophoretic techniques for the in-depth characterization of protein-based therapeutics.
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.